Genentech’s Obinutuzumab (GA101) Delayed Disease Progression Longer Than Rituxan® in People with One of the Most ... Genentech, a member of the Roche Group , today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening compared to Rituxan® plus chlorambucil.
July 24, 2013 - Business Wire via Yahoo! Finance